Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Aura Biosciences Inc ( (AURA) ) has shared an update.
On April 30, 2026, Aura Biosciences appointed veteran rare disease and oncology executive Natalie Holles as Chief Executive Officer, President and Class I director, succeeding founder Elisabet de los Pinos, who transitioned to a consulting role with an equity-vested separation package. Holles’ compensation includes a $700,000 base salary, performance-based bonus eligibility, and significant inducement equity awards and PRSUs, aligning her incentives with long-term shareholder value as she leads the company through late-stage development and potential commercialization of bel-sar.
On May 4, 2026, the company reported that its Phase 3 CoMpass trial of bel-sar in early choroidal melanoma was nearing full enrollment, with 86 patients enrolled and more than 25 additional patients scheduled or identified for screening, while reiterating expectations to complete enrollment by mid-2026 and report topline data in the second half of 2027. Aura also terminated the existing at-the-market offering prospectus with Jefferies after having raised about $6.7 million under the program, signaling a shift in its financing approach as it advances a registration-enabling study that could strengthen its position in ocular oncology if results are positive.
The most recent analyst rating on (AURA) stock is a Buy with a $24.00 price target. To see the full list of analyst forecasts on Aura Biosciences Inc stock, see the AURA Stock Forecast page.
Spark’s Take on AURA Stock
According to Spark, TipRanks’ AI Analyst, AURA is a Neutral.
The score is primarily constrained by weak financial performance typical of a pre-revenue biotech—widening losses and increasing cash burn—despite a relatively low-debt balance sheet. Technical indicators are neutral-to-mildly constructive, but valuation support is limited by negative earnings and no dividend yield.
To see Spark’s full report on AURA stock, click here.
More about Aura Biosciences Inc
Aura Biosciences, Inc. is a Boston-based, clinical-stage biotechnology company developing precision therapies for solid tumors with the aim of preserving organ function. Its lead candidate, belzupacap sarotalocan (bel-sar, AU-011), is in late-stage development for early choroidal melanoma and in early-stage development for additional ocular oncology indications and bladder cancer, targeting rare oncology markets with high unmet need.
Average Trading Volume: 270,276
Technical Sentiment Signal: Hold
Current Market Cap: $450M
For detailed information about AURA stock, go to TipRanks’ Stock Analysis page.